STOCK TITAN

Exozymes grants director Rayo 25,000 stock options

The options vest over twelve quarterly installments through September 30, 2029, subject to the director's continued service.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Exozymes Inc. director Edgardo Javier Rayo received a grant of 25,000 stock options on October 1, 2026, with an exercise price of $6.28 per share and an expiration date of October 1, 2033. The options vest in twelve quarterly installments: eleven installments of 2,083 shares and a final installment of 2,087 shares, beginning December 31, 2026 and ending September 30, 2029, subject to his continued service. The report also lists his direct ownership of 77,909 common shares on October 1, 2026.

Insider Rayo Edgardo Javier
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) F1 25,000 $0.00 $0.00
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct); Common Stock — 77,909 shares (Direct)
Footnotes (1)
  1. F1. The option vests in twelve (12) quarterly installments, consisting of eleven (11) installments of 2,083 shares and a final installment of 2,087 shares, beginning on 12/31/2026 and ending on 09/30/2029, subject to the reporting person's continued service with the issuer. The option expires on 10/01/2033.
Stock options awarded 25,000 options Grant dated October 1, 2026
Exercise price $6.28 per share Stock options granted October 1, 2026
Expiration date October 1, 2033 Stock options granted October 1, 2026
Direct common shares 77,909 shares Reported holding on October 1, 2026
Vesting installments 12 quarterly installments Beginning December 31, 2026 and ending September 30, 2029
Installment amounts 11 installments of 2,083 shares Option vesting schedule
Final installment 2,087 shares Option vesting schedule
Stock Option (right to buy) financial
"Stock Option (right to buy)"
exercise price financial
"exercise price of $6.28 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests financial
"The option vests in twelve (12) quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What options did EXOZ director Edgardo Javier Rayo receive?

Edgardo Javier Rayo received 25,000 stock options on October 1, 2026, with an exercise price of $6.28 per share and an expiration date of October 1, 2033.

How do Edgardo Javier Rayo's EXOZ options vest?

The options vest in twelve quarterly installments: eleven installments of 2,083 shares and a final installment of 2,087 shares, beginning December 31, 2026 and ending September 30, 2029, subject to his continued service with Exozymes Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rayo Edgardo Javier

(Last)(First)(Middle)
C/O 750 ROYAL OAKS DRIVE, SUITE 106

(Street)
MONROVIA CALIFORNIA 91016

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock77,909D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$6.2810/01/2026A25,000 (1)10/01/2033Common Stock25,000$0.0025,000D
Explanation of Responses:
1. The option vests in twelve (12) quarterly installments, consisting of eleven (11) installments of 2,083 shares and a final installment of 2,087 shares, beginning on 12/31/2026 and ending on 09/30/2029, subject to the reporting person's continued service with the issuer. The option expires on 10/01/2033.
/s/ Edgardo Rayo10/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading